FibroGen, Inc. (0IL8.L)
USD 0.36
(3.62%)
USD 0.36
(3.62%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -284.23 Million USD | 3.72% |
| 2022 | -295.22 Million USD | -1.44% |
| 2021 | -291.03 Million USD | -53.75% |
| 2020 | -189.29 Million USD | -145.93% |
| 2019 | -76.97 Million USD | 10.93% |
| 2018 | -86.42 Million USD | 31.52% |
| 2017 | -126.2 Million USD | -104.61% |
| 2016 | -61.68 Million USD | 28.09% |
| 2015 | -85.77 Million USD | -44.16% |
| 2014 | -59.5 Million USD | -298.21% |
| 2013 | -14.94 Million USD | 54.12% |
| 2012 | -32.57 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -15.54 Million USD | 52.8% |
| 2024 Q1 | -32.93 Million USD | 41.43% |
| 2023 Q3 | -63.61 Million USD | 27.45% |
| 2023 Q4 | -56.23 Million USD | 11.61% |
| 2023 Q1 | -77.5 Million USD | -16.62% |
| 2023 Q2 | -87.68 Million USD | -13.13% |
| 2023 FY | -284.23 Million USD | 3.72% |
| 2022 Q4 | -66.45 Million USD | 27.49% |
| 2022 FY | -295.22 Million USD | -1.44% |
| 2022 Q3 | -91.65 Million USD | -25.22% |
| 2022 Q2 | -73.18 Million USD | -15.21% |
| 2022 Q1 | -63.52 Million USD | 52.62% |
| 2021 FY | -291.03 Million USD | -53.75% |
| 2021 Q2 | -133.98 Million USD | -86.73% |
| 2021 Q4 | -134.07 Million USD | -369.25% |
| 2021 Q3 | 49.79 Million USD | 137.17% |
| 2021 Q1 | -71.75 Million USD | -22.38% |
| 2020 FY | -189.29 Million USD | -145.93% |
| 2020 Q1 | -78.34 Million USD | 20.15% |
| 2020 Q2 | -85.31 Million USD | -8.89% |
| 2020 Q3 | 33 Million USD | 138.69% |
| 2020 Q4 | -58.63 Million USD | -277.66% |
| 2019 Q4 | -98.12 Million USD | -98.47% |
| 2019 FY | -76.97 Million USD | 10.93% |
| 2019 Q3 | -49.43 Million USD | -142.62% |
| 2019 Q2 | 116 Million USD | 355.45% |
| 2019 Q1 | -45.41 Million USD | -316.73% |
| 2018 Q3 | -42.55 Million USD | -81.71% |
| 2018 Q4 | 20.95 Million USD | 149.24% |
| 2018 Q1 | -41.39 Million USD | -87.13% |
| 2018 Q2 | -23.42 Million USD | 43.42% |
| 2018 FY | -86.42 Million USD | 31.52% |
| 2017 FY | -126.2 Million USD | -104.61% |
| 2017 Q3 | -37.73 Million USD | -13.72% |
| 2017 Q1 | -33.16 Million USD | 2.47% |
| 2017 Q2 | -33.18 Million USD | -0.07% |
| 2017 Q4 | -22.12 Million USD | 41.38% |
| 2016 FY | -61.68 Million USD | 28.09% |
| 2016 Q4 | -34 Million USD | -40.77% |
| 2016 Q3 | -24.15 Million USD | -199.33% |
| 2016 Q2 | 24.31 Million USD | 187.34% |
| 2016 Q1 | -27.84 Million USD | 45.8% |
| 2015 FY | -85.77 Million USD | -44.16% |
| 2015 Q4 | -51.36 Million USD | -13.91% |
| 2015 Q3 | -45.09 Million USD | -179.04% |
| 2015 Q2 | 57.05 Million USD | 223.05% |
| 2015 Q1 | -46.36 Million USD | 8.29% |
| 2014 Q2 | 46.83 Million USD | 388.37% |
| 2014 Q4 | -50.56 Million USD | -27.89% |
| 2014 Q3 | -39.53 Million USD | -184.42% |
| 2014 FY | -59.5 Million USD | -298.21% |
| 2014 Q1 | -16.24 Million USD | 39.34% |
| 2013 Q1 | -18.17 Million USD | 0.0% |
| 2013 Q3 | 39.3 Million USD | 522.75% |
| 2013 Q2 | -9.29 Million USD | 48.85% |
| 2013 Q4 | -26.77 Million USD | -168.12% |
| 2013 FY | -14.94 Million USD | 54.12% |
| 2012 FY | -32.57 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | -85.507% |
| Dynavax Technologies Corporation | -6.38 Million USD | -4348.771% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 21698.176% |
| Perrigo Company plc | -12.7 Million USD | -2138.047% |
| Illumina, Inc. | -1.16 Billion USD | 75.518% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 104.741% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 35.989% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 96.709% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 120.93% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -157.086% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 107.189% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -613.076% |
| Waters Corporation | 642.23 Million USD | 144.257% |
| Biogen Inc. | 1.16 Billion USD | 124.48% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | -10.24% |
| Evolus, Inc. | -61.68 Million USD | -360.78% |
| Adicet Bio, Inc. | -142.65 Million USD | -99.24% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -139.832% |
| bluebird bio, Inc. | -211.91 Million USD | -34.127% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | -35.835% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 122.922% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -537.244% |
| Homology Medicines, Inc. | -53.74 Million USD | -428.873% |
| Geron Corporation | -184.12 Million USD | -54.367% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 35.437% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -87.508% |
| Myriad Genetics, Inc. | -112 Million USD | -153.779% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -230.906% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 40.932% |
| Zoetis Inc. | 2.34 Billion USD | 112.126% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -424.529% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 136.034% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 269.544% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 107.853% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -573.552% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 22.402% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | -2.936% |
| Verastem, Inc. | -87.36 Million USD | -225.331% |
| Nektar Therapeutics | -276.05 Million USD | -2.962% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | -18.807% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -221.235% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 46.969% |
| OPKO Health, Inc. | -188.86 Million USD | -50.496% |
| Exelixis, Inc. | 207.76 Million USD | 236.805% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 213.829% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 367.79% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -498.32% |
| uniQure N.V. | -308.47 Million USD | 7.86% |
| Imunon, Inc. | -19.51 Million USD | -1356.481% |
| Blueprint Medicines Corporation | -506.98 Million USD | 43.937% |
| Insmed Incorporated | -749.56 Million USD | 62.081% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 200.937% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 19.272% |
| TG Therapeutics, Inc. | 12.67 Million USD | 2342.992% |
| Incyte Corporation | 597.59 Million USD | 147.562% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 62.626% |